MAPK3 and hepatocellular carcinoma: Sorafenib, a Raf-1 kinase inhibitor, was the first systemic drug approved by the FDA for the treatment of advanced HCC; it improved the overall survival rate and delayed the time to progression [7], indicating that the ERK1/2 pathway is a major driver in HCC.